| Bid | 0.65 |
| Market Cap | 11.38M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -0.91 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.76 |
| Volume | 121,042 |
| Avg. Volume (20D) | 207,791 |
| Open | 0.70 |
| Previous Close | 0.75 |
| Day's Range | 0.70 - 0.76 |
| 52-Week Range | 0.67 - 3.62 |
| Beta | undefined |
About BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas....
Analyst Forecast
According to 1 analyst ratings, the average rating for BIAF stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 721.92% from the latest price.
Next Earnings Release
Analysts project revenue of $2.42M, reflecting a 9.35% YoY growth and earnings per share of -0.14, making a -46.15% decrease YoY.
4 weeks ago · businesswire.com
Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19.
2 months ago · businesswire.com
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private PlacementSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement.
2 months ago · businesswire.com
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private PlacementSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.